These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3508339)

  • 1. The need for characterization of pathogenicity genes of recombinant DNA viruses used as human vaccines.
    Becker Y
    Virus Genes; 1987 Nov; 1(1):117-20. PubMed ID: 3508339
    [No Abstract]   [Full Text] [Related]  

  • 2. Public health. Looking for vaccines that pack a wallop without the side effects.
    Cohen J
    Science; 2002 Dec; 298(5602):2314. PubMed ID: 12493891
    [No Abstract]   [Full Text] [Related]  

  • 3. [Peroral immunization--a method for enhancing the safety of the recombinant vector (the vaccinia virus)].
    Podkuĭko VN; Vorob'ev AA; Krasnianskiĭ VP; Patrikeev GT; Mikhaĭlov VV; Dorokhina TV; Makhlaĭ AA; Dykanov GA
    Vestn Ross Akad Med Nauk; 1993; (2):39-44. PubMed ID: 7688619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine.
    Gurvich EB
    Vaccine; 1992; 10(2):96-7. PubMed ID: 1347190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular biology of vaccinia virus and development of a new type of vaccine].
    Shida H
    Uirusu; 1986 Jun; 36(1):23-33. PubMed ID: 3535240
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccinia virus: a suitable vehicle for recombinant vaccines?
    Kaplan C
    Arch Virol; 1989; 106(1-2):127-39. PubMed ID: 2669685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered poxviruses: a novel approach to the construction of live vaccines.
    Paoletti E; Weinberg RL; Davis SW; Davis M
    Vaccine; 1984 Sep; 2(3):204-8. PubMed ID: 6099648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinia virus: a tool for research and vaccine development.
    Moss B
    Science; 1991 Jun; 252(5013):1662-7. PubMed ID: 2047875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New technology of vaccine production--international prospect of the development. Method and theory of production of vaccines by genetic engineering. a. Vaccinia vector vaccine].
    Hashizume S; Morita M; Takahashi F
    Nihon Rinsho; 1987 Oct; 45(10):2333-41. PubMed ID: 3482288
    [No Abstract]   [Full Text] [Related]  

  • 11. Live recombinant vaccines using genetically engineered vaccinia virus.
    Paoletti E; Perkus ME; Piccini A
    Antiviral Res; 1985; Suppl 1():301-7. PubMed ID: 3866514
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccinia from recombinant virus expressing HIV genes.
    Guillaume JC; Saiag P; Wechsler J; Lescs MC; Roujeau JC
    Lancet; 1991 Apr; 337(8748):1034-5. PubMed ID: 1673182
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP).
    MMWR Recomm Rep; 1991 Dec; 40(RR-14):1-10. PubMed ID: 1660957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a vaccinia virus strain used to produce smallpox vaccine in Argentina between 1937 and 1970.
    Lewis A; Bok K; Perez O; DeFillippo J; Paolazzi C; Gomez JA
    Arch Virol; 2005 Jul; 150(7):1485-91. PubMed ID: 15750861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New technology of vaccine production--international prospect of the development. Method and theory of production of vaccines by genetic engineering. b. Trials of development of recombinant vaccinia polyvaccines].
    Yasuda A; Kojima A
    Nihon Rinsho; 1987 Oct; 45(10):2342-8. PubMed ID: 3129603
    [No Abstract]   [Full Text] [Related]  

  • 17. Biodefense. Smallpox vaccines: looking beyond the next generation.
    Enserink M
    Science; 2004 May; 304(5672):809. PubMed ID: 15131277
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccinia and other poxvirus expression vectors.
    Moss B
    Curr Opin Biotechnol; 1992 Oct; 3(5):518-22. PubMed ID: 1368937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
    Moss B
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11341-8. PubMed ID: 8876137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of recombinant vaccinia vaccines.
    Baxby D
    Lancet; 1991 Apr; 337(8746):913. PubMed ID: 1672987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.